NCT04342975 is a Phase 2 clinical trial of Nicotinamide Riboside + Pterostilbene in AKI, sponsored by Mayo Clinic.

Who is sponsoring NCT04342975?

NCT04342975 is sponsored by Mayo Clinic.

What drugs are being tested in NCT04342975?

Interventions in NCT04342975: Nicotinamide Riboside + Pterostilbene, Placebo.

Is NCT04342975 still recruiting?

NCT04342975 is currently completed. Last updated 23 April 2024.

Last reviewed 2024-04-23 · How we verify

NCT04342975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

Completed Phase 2 Last updated 23 April 2024

What this trial tests

Phase 2 trial testing Nicotinamide Riboside + Pterostilbene in AKI in 54 participants. Completed in 14 March 2024.

Timeline

1 December 2020

Primary endpoint
14 March 2024

14 March 2024

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	54
Start date	1 December 2020
Primary completion	14 March 2024
Estimated completion	14 March 2024
Sites	1 location across United States

Drugs / interventions tested

Nicotinamide Riboside + Pterostilbene — full drug profile →
Placebo

Conditions studied

AKI — all drugs for AKI →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with AKI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.
Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7
Acute kidney injury in the critically ill: an updated review on pathophysiology and management.
Pickkers P, Darmon M, Hoste E, Joannidis M, et al · · 2021 · cited 354× · PMID 34213593 · DOI 10.1007/s00134-021-06454-7
More Than Resveratrol: New Insights into Stilbene-Based Compounds.
Pecyna P, Wargula J, Murias M, Kucinska M. · · 2020 · cited 87× · PMID 32726968 · DOI 10.3390/biom10081111
New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects.
Nagarajan S, Mohandas S, Ganesan K, Xu B, et al · · 2022 · cited 57× · PMID 36234852 · DOI 10.3390/molecules27196316
New drugs for acute kidney injury.
Pickkers P, Murray PT, Ostermann M. · · 2022 · cited 33× · PMID 35999470 · DOI 10.1007/s00134-022-06859-y
Roles of NAD+ in Acute and Chronic Kidney Diseases.
Morevati M, Fang EF, Mace ML, Kanbay M, et al · · 2022 · cited 28× · PMID 36613582 · DOI 10.3390/ijms24010137
Nicotinamide and acute kidney injury.
Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, et al · · 2021 · cited 22× · PMID 34950458 · DOI 10.1093/ckj/sfab173
NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease.
Chanvillard L, Tammaro A, Sorrentino V. · · 2022 · cited 19× · PMID 36611814 · DOI 10.3390/cells12010021

Verify or expand the search:

Other recruiting trials for AKI

Currently open trials in the same condition.

NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT06596811 — Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based · active not recruiting
NCT06596798 — Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury · active not recruiting
NCT04216927 — NO During CPB in Neonates to Reduce Risk of AKI · Phase 3 · recruiting
NCT04114747 — Renal Physiology During Continuous Renal Replacement Therapy · NA · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04342975 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04342975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing